Unigene to support Stealth phase 1 study for drug candidates
Stealth decided to move forward with Unigene’s platform following the data of an oral feasibility study for its pipeline candidate using the latter’s oral delivery technology relative to
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.